Tauklarify is a brain PET tracer approved in 2026 to show tau tangles in adults with memory problems being checked for Alzheimer's. Tau tangles are twisted clumps of tau protein inside brain cells that damage memory circuits. The scan helps doctors place memory symptoms in context and plan next steps. It does not replace a clinical exam, memory testing, or other workup.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the scan shows
- How consistent are readings
- What results cannot decide alone
- What happens on scan day
What the scan shows
Tauklarify, previously studied as MK-6240, is an F-18 radioactive tracer that sticks to clumped tau and makes tangles visible on PET, according to NeurologyLive in its approval report. The signal gives a visual map of tangle pathology. Doctors read the image as positive or negative for tau.
It is meant for adults with cognitive impairment being evaluated for Alzheimer's to identify tau tangle pathology, according to the Enigma Biomedical USA press release in the FDA approval notice. Enigma developed the agent and sold subsidiary Cerveau Technologies to Lantheus in 2023 to finish development and commercialization. That history matters because prescribing information and distribution now come through Lantheus.
How consistent are readings
Approval rested on two blinded-read studies in 617 participants where five independent readers scored scans positive or negative, according to Pharmacy Times in its approval summary. Positive agreement was 68%-88% and negative agreement was 93%-99%. Those numbers describe reader agreement against a reference, not perfect detection in every patient.
Readers agreed strongly on binary tau status, with Fleiss kappa about 0.86-0.92, supporting use across centers for memory-clinic staging including early impairment, according to NeurologyLive. Strong agreement helps families compare results between clinics. It still leaves room for borderline scans that need clinical judgment.
What results cannot decide alone
A positive scan alone does not confirm tau pathology and a negative scan does not exclude it. Safety and effectiveness are not established for non-Alzheimer tauopathies, such as movement disorders linked to different tau forms. The result must fit symptoms, history, cognitive scores, and other tests.
Safety data in 1,734 recipients showed mostly mild events, most commonly headache at 0.7% and nausea at 0.2%. Labeling still warns about cumulative radiation exposure and misdiagnosis risk without clinical correlation. Patients should discuss prior scans, radiation exposure, and diagnostic uncertainty with the ordering doctor.
What happens on scan day
Patients receive a single 185 MBq (5 mCi) intravenous bolus. The visit includes hydration and guidance to void often before and after imaging.
The tracer dose is fixed, not adjusted by weight. Ask the clinic about these practical steps: Bring a full drug, supplement, and smoking history to the appointment. Confirm who will explain the binary result and what follow-up is planned.
- drink fluids and empty the bladder as directed to lower bladder radiation
- avoid CYP1A2 inducers, including smoking, for 7 days before injection
- interrupt breastfeeding for 4 hours after injection and discard that milk
You Might Also Like
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: What Memory Clinic Patients Should Know About the News
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Memory Clinic Patients Should Know About the News
- Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: What Changed and What Did Not for Family Caregivers
